MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Adial Pharmaceuticals Total Shareholders Equity 2011-2026 | ADIL
Annual Total Shareholders Equity Adial Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.07 M | 4.08 M | 3.28 M | 3.51 M | 3.99 M | 7.14 M | 4.44 M | -998 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.14 M | -998 K | 3.69 M |
Quarterly Total Shareholders Equity Adial Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.51 M | 5.59 M | 2.13 M | 4.07 M | 5.88 M | 4.28 M | 4.08 M | 2.34 M | 3.32 M | 1.44 M | 3.28 M | 5.41 M | 7.96 M | 10.7 M | 3.51 M | 7.2 M | 4.83 M | 5.62 M | 3.99 M | 3.99 M | 3.99 M | 3.99 M | 7.14 M | 7.14 M | 7.14 M | 7.14 M | 4.44 M | 4.44 M | 4.44 M | 4.44 M | -998 K | -998 K | -998 K | - | -103 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.7 M | -998 K | 4.27 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
ADMA Biologics
ADMA
|
477 M | $ 16.49 | -0.3 % | $ 3.93 B | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.59 | -1.1 % | $ 1.07 B |  Canada |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.5 | 3.22 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.81 | -1.57 % | $ 4.42 M | China |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
404 M | $ 75.14 | -1.82 % | $ 1.45 B | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.57 | -3.68 % | $ 401 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
88.3 M | $ 163.09 | -0.61 % | $ 8.11 B | USA |
 |
Champions Oncology
CSBR
|
3.77 M | $ 6.0 | - | $ 82 M | USA |
 |
BridgeBio Pharma
BBIO
|
-2.09 B | $ 65.5 | -1.57 % | $ 12.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-7.76 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
22 M | $ 2.84 | 1.07 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 60.3 | -0.22 % | $ 11.6 B | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.34 | -0.48 % | $ 1.36 B | Britain |
 |
Cabaletta Bio
CABA
|
236 M | $ 3.37 | -1.75 % | $ 3.94 M | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-160 M | $ 3.04 | -5.0 % | $ 1.09 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
16.3 M | $ 0.59 | - | $ 549 K | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Capricor Therapeutics
CAPR
|
22.6 M | $ 25.56 | 0.22 % | $ 684 M | USA |